Avid Bioservices Inc (CDMO)

[biopharm]

Dr. Rolf Brekken : Peregrine Pharmaceuticals KOL :

follow the puzzle pieces, leads to Kolltan and Gilead...and licensing of IP from Medimmune ( = AstraZeneca) and...???

October 15, 2015 @ 04:00 PM
Pharmacology and Cancer Cell Networks Program Seminar Series

Greg E. Lemke, PhD, Salk Institute for Biological Studies. Biology of the TAM Receptors.

Rolf A. Brekken, PhD, host. Pickens Biomedical Bldg. (ND) 7.218.
Event Information

Event Starts
October 15, 2015 @ 04:00 PM

Event Ends
October 15, 2015 @ 05:00 PM

Location
T. Boone Pickens Biomedical Research Building (ND)
7.218
Maps & Directions

Contact
Velia Soper
214-645-6127

http://www.utsouthwestern.edu/life-at/events/eventDetails.html?eventId=CAL-47726ad4-4fe0287e-0150-0019fd1e-00000e79demobedework%40mysite.edu

.... remember Greg at Keystone Symposia and other Peregrine collaborators there I would say

Greg E. Lemke
, The Salk Institute for Biological Studies, USA
TAM Signaling in Macrophages and DCs

https://www.keystonesymposia.org/index.cfm?e=Web.Meeting.Flyer&MeetingID=1336

----------------------------

...remember also ps related patents bought out by Kolltan

Greg Lemke and Salks and Exterios Therapeutics....all patents...(some PS related patents)..etc bought out by Kolltan

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111883097

Why would Kolltan head to AACR with leaving details out of abstracts such as with... "other surface antigens" and possibly PS / receptors...? Secretly witholding details Peregrine like...

http://investorshub.advfn.com/boards/replies.aspx?msg=111883097

-----------------------------

Now all of a sudden Greg Lemke coming over to UTSWM with our very own Rolf Brekken as host?? hmmmm...

----------------------------

Kolltan update:

Cancer biotech Kolltan Pharmaceuticals withdraws $86 million IPO

Read more: www.nasdaq.com/article/cancer-biotech-kolltan-pharmaceuticals-withdraws-86-million-ipo-cm437690#ixzz3mn1BZ1Ey


Kolltan Pharmaceuticals, an early-stage biotech developing antibodies to treat solid tumors, withdrew its plans for an initial public offering on Wednesday. The company originally filed for an $86 million IPO in September 2014.

Kolltan is in Phase 1 trials for antibody-based drugs that target receptor tyrosine kinases (RTKs). It licenses IP from MedImmune, which has the option to receive future payments based on the value of Kolltan's lead drug candidate. Kolltan is also in preclinical development of certain inflammatory diseases and other cancers.

Primary shareholders include Fidelity Investments, KLP Enterprises, Gilead Sciences (GILD), Auven Therapeutics and co-founders Joseph Schlessinger and Arthur Altschul.

The New Haven, CT-based company was founded in 2007, had planned to list on the NASDAQ under the symbol KLTN. Leerink Partners and Stifel were set to be the joint bookrunners on the deal.

Read more: http://www.nasdaq.com/article/cancer-biotech-kolltan-pharmaceuticals-withdraws-86-million-ipo-cm437690#ixzz3mn14KKA9

http://www.nasdaq.com/article/cancer-biotech-kolltan-pharmaceuticals-withdraws-86-million-ipo-cm437690